A Phase 3 Clinical Trial to Evaluate Efficacy and Safety of Twice-daily Applications of Delgocitinib Cream 20 mg/g Compared With Cream Vehicle for a 16-week Treatment Period in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema (DELTA TEEN)
Latest Information Update: 06 Jul 2026
At a glance
- Drugs Delgocitinib (Primary)
- Indications Eczema
- Focus Registrational; Therapeutic Use
- Acronyms DELTA-TEEN
- Sponsors LEO Pharma
Most Recent Events
- 25 Jun 2026 According to a Leo Pharma media release, the key results from the DELTA Teen trial were published in The Lancet Child & Adolescent Health in earlyJune 2026.
- 25 Jun 2026 According to a Leo Pharma media release, results form this trial presented at the ESCD 2026.
- 25 Jun 2026 Results presented in the Leo Pharma Media Release.